Previous clinical studies have shown that circulating MCP-1 levels are significantly increased in patients with IPAH and negatively correlated with disease duration, suggesting the involvement of MCP-1 in the PAH pathological process (Figure 2) [101]. The gene discussed is CCL2; the disease is pulmonary arterial hypertension.